Which companies overlap with Institut für Pharmakologie und Präventive Medizin's portfolio?

Top competitors by shared drug class: , Boehringer Ingelheim, Boryung Pharmaceutical Co., Ltd, COLM Study Research Organization, Chong Kun Dang Pharmaceutical.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/institut-f-r-pharmakologie-und-pr-ventive-medizin.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-18 · How we verify

Institut für Pharmakologie und Präventive Medizin — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Institut für Pharmakologie und Präventive Medizin pipeline: 2 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Olmesartan/amlodipine	Olmesartan/amlodipine	marketed	Angiotensin II receptor blocker / Calcium channel blocker combination	AT1 receptor (angiotensin II type 1 receptor) / L-type calcium channel	Cardiovascular
Empagliflozin and Linagliptin	Empagliflozin and Linagliptin	marketed	Dipeptidyl Peptidase 4 Inhibitor [EPC]
Metformin and Insulin sc	Metformin and Insulin sc	phase 3	SGLT2 inhibitor and insulin		Diabetes
Olmesartan/Amlodipin	Olmesartan/Amlodipin	phase 3	Angiotensin II receptor blocker / Calcium channel blocker combination	AT1 receptor (angiotensin II type 1 receptor) / L-type calcium channel	Cardiovascular

Therapeutic area mix

Cardiovascular · 2
Diabetes · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

· 1 shared drug class
Boehringer Ingelheim · 1 shared drug class
Boryung Pharmaceutical Co., Ltd · 1 shared drug class
COLM Study Research Organization · 1 shared drug class
Chong Kun Dang Pharmaceutical · 1 shared drug class
Daiichi Sankyo Co., Ltd. · 1 shared drug class
Generic (originally Merck Serono/Lipha) · 1 shared drug class
HK inno.N Corporation · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Institut für Pharmakologie und Präventive Medizin:

Cite this brief

Drug Landscape (2026). Institut für Pharmakologie und Präventive Medizin — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/institut-f-r-pharmakologie-und-pr-ventive-medizin. Accessed 2026-05-18.